ATS 2020 Virtual is scheduled to be held from August 5 to August 10, and it is exciting to watch the key presentations by Pharmaceutical Companies specifically focused on pulmonary disease, critical illness, and sleep disorders.
Boehringer Ingelheim presented new analyses of Ofev data in patients with chronic fibrosing ILDs during the American Thoracic Society (ATS) Virtual conference
Boehringer Ingelheim is worth mentioning here, as it is presenting key posters and studies on Ofev’s SENSCIS Trial and INBUILD Trial.
Ofev (Nintedanib) Facts
Nintedanib is an orally bioavailable, small-molecule tyrosine kinase inhibitor (TKI) developed for the treatment of I...
